Article

Fungal Infections of Implantation: More Than Five Years of Cases of Subcutaneous Fungal Infections Seen at the UK Mycology Reference Laboratory

Andrew M. Borman 1,2,*, Mark Fraser 1, Zoe Patterson 1, Christopher J. Linton 1, Michael Palmer 1 and Elizabeth M. Johnson 1,2

1 UK Health Security Agency National Mycology Reference Laboratory, Southmead Hospital, Bristol BS10 5NB, UK; mark.fraser@nbt.nhs.uk (M.F.); zoe.patterson@nbt.nhs.uk (Z.P.); chris.linton@nbt.nhs.uk (C.J.L.); michael.palmer@nbt.nhs.uk (M.P.); elizabeth.johnson@nbt.nhs.uk (E.M.J.)
2 Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter EX4 4QD, UK
* Correspondence: andy.borman@nbt.nhs.uk; Tel.: +44-0117-414-6286

Abstract: Subcutaneous fungal infections, which typically result from traumatic introduction (implantation) of fungal elements into the skin or underlying tissues, can present as a range of different clinical entities including phaeohyphomycosis, chromoblastomycosis, subcutaneous nodules or masses, and genuine eumycetoma. Here, we mined our laboratory information management system for such infections in humans and domestic animals for the period 2016–2022, including (i) fungal isolates referred for identification and/or susceptibility testing; (ii) infections diagnosed at our laboratory using panfungal PCR approaches on infected tissue; and (iii) organisms cultured in our laboratory from biopsies. In total, 106 cases were retrieved, involving 39 fungal species comprising 26 distinct genera. Subcutaneous infections with *Alternaria* species were the most frequent (36 cases), which possibly reflects the ubiquitous nature of this common plant pathogen. A substantial proportion of *Alternaria* spp. isolates exhibited reduced in vitro susceptibility to voriconazole. Notably, a significant number of subcutaneous infections were diagnosed in renal and other solid organ transplant recipients post transplantation, suggesting that humans may harbour “inert” subcutaneous fungal elements from historical minor injuries that present as clinical infections upon later immunosuppression. The current study underscores the diversity of fungi that can cause subcutaneous infections. While most organisms catalogued here were responsible for occasional infections, several genera (*Alternaria, Exophiala, Phaeoacremonium, Scedosporium*) were more frequently recovered in our searches, suggesting that they possess virulence factors that facilitate subcutaneous infections and/or inhabit natural niches that make them more likely to be traumatically inoculated.

Keywords: subcutaneous fungal infections; antifungal susceptibility; *Alternaria*; eumycetoma; phaeohyphomycosis; solid organ transplant

1. Introduction

Subcutaneous fungal infections are thought to result from traumatic implantation of the causative fungal organism into the subcutaneous tissue. As such, human cases of infection are observed more commonly in warmer climates and have been reported mainly in immunocompromised hosts [1–4]. Due to their foraging/hunting tendencies, similar infections are also frequently encountered in otherwise healthy domestic companion animals, in particular cats and dogs [5,6]. In humans, the exact disease presentation depends on the etiological agent involved but is also influenced to some extent by the exact host immunological status [7]. Subcutaneous phaeohyphomycosis is a localized infection caused by a wide and heterogenous range of dematiaceous (melanised) fungi and commonly presents as a well-encapsulated solitary nodule or subcutaneous mass on the extremities, near the site of previous trauma [8,9].
Chromoblastomycosis shares many similar features to phaeohyphomycosis: the etiological agents are melanised fungi and a number of distinct genera have been repeatedly implicated as causative agents and prevalence is, again, the greatest in tropical and sub-tropical locations. However, chromoblastomycosis can be distinguished from phaeohyphomycosis by the presence of distinctive muriform cells (sclerotic bodies) scattered singly or in clusters throughout granulomatous tissue, as reviewed in [10]. Moreover, while successful treatment of the localized nodules or subcutaneous masses typical of phaeohyphomycosis can often be achieved via surgical excision (with or without adjunctive antifungal therapy), the lesions associated with chromoblastomycosis are often more extensive and recalcitrant to treatment, with frequent recurrence [10]. Finally, eumycetoma is a chronic but progressive infection of the skin, subcutaneous tissues and eventually bone, characterised by the diagnostic triad of relatively painless but relentlessly enlarging subcutaneous mass, development of sinus tracts that exude sero-purulent discharge and the presence of fungal grains in discharge and tissue [11–13]. A growing number of distinct fungal agents of eumycetoma have been described to date, spanning several fungal orders [12,13].

All of the above manifestations present diagnostic and therapeutic challenges: the subcutaneous lesions/swellings are indolent in onset with generally slow progression, such that records of historical trauma at the site are often vague; medical intervention is also frequently sought relatively late in disease progression, especially in regions where access to healthcare can be challenging; and many of the agents associated with subcutaneous fungal infections exhibit reduced antifungal drug susceptibility in vitro and successful treatment usually requires surgical interventions coupled with protracted treatment with antifungal agents. The fact that many case reports and case series highlight the occurrence of all forms of subcutaneous mycoses in solid organ transplant recipients, and in particular renal transplant patients [7,14–18], further complicates treatment due to the challenges of employing many of the newer triazole antifungal agents in patients receiving tacrolimus.

The UK National Mycology Reference Laboratory (MRL), part of the UK Health Security Agency (UKHSA), provides a comprehensive service for the diagnosis and management of fungal disease. The MRL portfolio includes serological and fungal biomarker tests to aid the diagnosis of both superficial and invasive/systemic fungal infections, microscopy and culture and panfungal PCR analyses of respiratory secretions, biopsies and tissues where appropriate, identification and susceptibility testing of isolates of pathogenic yeast and moulds (filamentous fungi), both isolated at the MRL and referred from other laboratories, and therapeutic drug monitoring of serum drug concentrations in patients receiving antifungal therapy. Samples for testing are referred to the MRL from hospitals, microbiology laboratories and veterinary and general practitioner services across the UK.

Here, we have analysed >5 years of MRL laboratory data to identify probable and proven cases of subcutaneous infections in humans and domestic companion animals, collating supporting clinical data, the methods of diagnosis/identification and antifungal susceptibility profiles of the causative agents (where available). As many cases of fungal keratitis also result from traumatic injury to the cornea [19,20], such cases were also retrieved during database analyses and included in the study. The present results underscore the wide range of causative agents and clinical presentations associated with subcutaneous fungal infections.

2. Materials and Methods

In order to compile a comprehensive list of all fungal infections of implantation referred to the MRL, the laboratory information management system (LIMS) was interrogated for the period October 2016 (the date of implementation of a new LIMS) through to 2 February 2022. Three different searches were performed in parallel: (i) all isolates of moulds (filamentous fungi) from all clinical human and animal specimens that had been submitted to the MRL for identification and susceptibility testing; (ii) all isolates of moulds that had been recovered at the MRL from human and animal clinical specimens processed at the
MRL; and (iii) all panfungal PCR tests that had been performed at the MRL on human and animal samples where a positive PCR reaction was reported and successful identification of an organism was achieved by sequencing of PCR amplicons. These initial searches recovered 19,047 referred mould isolates, an additional 4919 mould isolates isolated at the MRL from the primary processing of clinical samples and 1854 positive panfungal PCR results.

Each individual dataset was then hand-edited to retain only listings that corresponded to possible subcutaneous infections (including keratitis as this is often an infection of implantation/trauma) by excluding all listings corresponding to non-cutaneous, subcutaneous or ocular sites. The resulting edited datasets were then examined entry-by-entry for relevant accompanying clinical information that would support a genuine diagnosis of subcutaneous/implantation mycosis, resulting in final datasets containing 92 referred isolates of mould, 30 additional isolates recovered in culture at the MRL, and 59 infections diagnosed by panfungal PCR and sequencing. After compilation of the three datasets and sorting by patient/animal identifiers, 106 individual cases of subcutaneous fungal infection were retained (certain cases had repeat isolation of the same organism on multiple occasions, others were confirmed both by isolation in primary culture and panfungal PCR of biopsy/tissues). Finally, where mould isolates had been recovered or referred to the MRL and susceptibility testing requested, the LIMS was interrogated with individual MRL sample reference numbers and available antifungal susceptibility results and methods employed for the identification of isolates or additional diagnostic modalities were collected.

All antifungal susceptibility testing at the MRL during this period was performed using the CLSI broth microdilution method M38-A2 [21] exactly as described previously [22]. Identification of isolates was performed by phenotypic examination, usually in combination with MALDI-TOF MS analyses and/or rDNA sequencing as described previously in [13,23]. The tissue processing, DNA extraction and panfungal PCR approaches employed during this period have also been described previously [24]; panfungal PCR was performed using the primers described previously, which target the D1/D2 regions of the 28S large ribosomal subunit, the ITS1 region and additional loci (actin, RNA polymerase second largest subunit and translation elongation factor 1α) where necessary [13,23].

3. Results

Searches of the MRL LIMS database for the period October 2016 through to 2 February 2022 returned a total of 106 separate cases of subcutaneous fungal infection or keratitis of likely traumatic origin. Cases involved 39 different fungal species encompassing 26 different genera (Table 1). Of note, 14/106 cases were reported in the recipients of solid organ transplants, most frequently renal transplant patients. For 34 of the 39 species implicated, searches retrieved 3 or less human or animal infections over the study period. However, Alternaria spp., Scedosporium apiospermum, Exophiala spp., Madurella spp. and Medicopsis romeroi were associated with significantly higher numbers of cases (42, 13, 9, 5 and 6 cases, respectively). This is perhaps unsurprising since Alternaria spp. are ubiquitous plant pathogens that are likely to be frequently associated with implantation injuries and keratitis in both humans and domestic animals who have accidents or aggressive interactions involving plant material, and Scedosporium apiospermum (a soil organism), Exophiala spp. and Medicopsis romeroi have frequently been associated in the existing literature with subcutaneous nodules and eumycetoma [5–9,13,16–18,20,23,25–28].

Table 2 describes the 64 non-Alternaria infections in more detail. All 38 species listed have been reported at least once previously as the causative agents of subcutaneous fungal infections or keratitis in humans or domestic animals. Indeed, at least 24 of the listed species have been consistently reported previously as significant causes of subcutaneous fungal infections, and in particular phaeohyphomycosis or eumycetoma. Moreover, 26 or the 64 cases in Table 2 (shown in bold) are definitively proven infections as evidenced by repeat isolations of the same organism from separate samples from usually sterile sites over many
weeks, months or years, recovery of the same organism in culture and by panfungal PCR of separate tissue samples, positive histological appearance consistent with the organism identified, positive fungal biomarker testing, history of previous penetrating injury at the site in a region endemic for that particular organism, or a combination of the above. Of note, the majority of infections were diagnosed in male patients (61%; 39/64), and of the human cases 69% occurred in patients aged 50 years or over (Table 2).

Table 1. The causative agents and clinical presentations associated with the 106 cases of subcutaneous fungal infection/traumatic keratitis retrieved in database searches.

| Organism (Number of Cases) | Clinical Presentation |
|----------------------------|-----------------------|
| **Subcutaneous infections:** |                       |
| Alternaria spp. (37)       | Subcutaneous masses, animals (26) |
|                            | Subcutaneous nodules in humans (11) following SOT (6) |
| Coccidioides immitis (1)    | Joint infection (knee) |
| Curvularia sp. (1)          | Soft tissue infection |
| Enarellia grisea (1)        | Fungal lesion, hand |
| Exophiala sp. (1)           | Shin nodule |
| Exophiala campbellii (1)    | Subcutaneous cyst |
| Exophiala dermatitidis (1)  | Subcutaneous swelling and skin plaques, foot |
| Exophiala jeanselmi (1)     | Subcutaneous mass |
| Exophiala lecanii-corni (1) | Cutaneous plaques and papules, arm |
| Exophiala oligosperma (1)   | Subcutaneous nodules |
| Exophiala xenobiotica (3)   | Infected ganglion (1), hand lesion (1), fungal mass in cat (1) |
| Exserohilum rostratum (1)   | Nasal mass |
| Falciformispora tompkinsii (1) | Phaeohyphomycosis |
| Fonsecaea monomorpha (2)    | Subcutaneous lesion (1), chromoblastomycosis (1) |
| Fusarium oxysporum complex (1) | Joint infection (knee) |
| Fusarium solani complex (1) | Eumycetoma |
| Kirschsteiniothelia rostrata (1) | Fungal abscess, foot. |
| Leptospora sp. (1)          | Joint infection (knee) |
| Madurella mycetomatis (3)   | Eumycetoma (3) |
| Madurella pseudomycetomatis (2) | Eumycetoma (2) incl. 1 in renal transplant patient |
| Medicopsis romeroi (6)      | Eumycetoma (3) |
|                            | Foot “ulcer” (1) |
|                            | Arm lesion, post renal transplant (1) |
|                            | Foot lesion, post renal transplant (1) |
| Microascus murinus (1)      | Foot lesion |
| Ochroconis tsawutscha (1)   | Fungal keratitis |
| Parathyridaria percutanea (2) | Skin nodules, renal transplant patient (1), skin lesions elbows and knees (1) |
| Phaeoacremonium spp. (1)    | Cystic lesions |
| Phaeoacremonium parasiticum (1) | Foot lesion |
| Phaeoacremonium rubrigenum (2) | Subcutaneous lesions in renal transplant patient (2) |
| Phaeoisaria clematidis (1)  | Arm abscess |
| Phialemoniopsis curvata (1)  | Skin nodule (foot), post renal transplant |
Table 1. Cont.

| Organism (Number of Cases) | Clinical Presentation                |
|----------------------------|-------------------------------------|
| Plectosphaerella cucumerina (1) | Tissue post tissue expanders         |
| Pseudallescheria ellipsoides (1) | Achilles abcess                      |
| Rhytidhysteron rufulum (1) | Ankle lesion                         |
| Sarocladium bactrocephalum (1) | Joint infection                      |
| Scedosporium apiospermum (10) | Subcutaneous nodules/lesions (7) post renal transplant (1) |
|                           | Joint infection (3)                  |
| Scedosporium aurantiacum (1) | Soft tissue infection                |
| Scedosporium de hoogii (1) | Joint infection (1)                  |
| Sporothrix brasiliensis (1) | Skin lesion/ulcer after cat scratch  |

Traumatic keratomycosis:
Alternaria spp. (5)
Cladosiphialophora boppii (1)
Curvularia hawaiiensis (1)
Scedosporium apiospermum (3)
Scedosporium de hoogii (1)

Table 2. Clinical presentation and mode of diagnosis of the 64 cases of infection caused by non-Alternaria species.

| Organism (Case Number) | Identification Method | Site                          | Clinical Presentation                                      |
|------------------------|-----------------------|-------------------------------|------------------------------------------------------------|
| Cladosiphialophora boppii | rDNA sequencing of isolate | Corneal scrape               | F 70y, query fungal keratitis                             |
| Coccidioides immitis    | Phenotypic ID of isolate | Joint fluid                  | M 86y, Joint infection (knee)                             |
| Curvularia sp.          | Phenotypic ID of isolate | Corneal scrape               | M 40y, microbial keratitis                                |
| Curvularia hawaiiensis  | MALDI-ToF MS of isolate | Foot tissue                  | M 68y, open dislocation of foot, RTA accident, Cambodia   |
| Emarellia grisea        | MALDI-ToF MS of isolate | Hand tissue                  | M 45y, Fungal lesion hand, site of previous eumycetoma    |
| Exophiala sp.           | Panfungal PCR of tissue | Elbow tissue                 | M 73y, keratotic, ulcerated lesion 6 months               |
| Exophiala campbellii    | MALDI-ToF MS of isolate | Subcutaneous cyst            | F 68y, encapsulated palmar cyst, confirmed by PCR of tissue|
| Exophiala dermatitidis  | MALDI-ToF MS of isolate | Tissue biopsy                | M 58y, Subcutaneous swelling, confirmed by PCR of tissue   |
| Exophiala jeannelsi    | MALDI-ToF MS of isolate | Subcutaneous mass            | F 45y, fluid aspirated from foot swelling                 |
| Exophiala lecanii-corni | MALDI-ToF MS of isolate | Skin biopsy                  | M 78y, cutaneous plaques/papules, arm; fungal elements seen|
| Exophiala oligosperma   | MALDI-ToF MS of isolate | Skin biopsy                  | F 52y, subcutaneous nodule, shin; fungal elements seen x2, isolated twice 5 mo |
| Exophiala xenobiotica (1) | MALDI-ToF MS of isolate | Tissue biopsy                | F 11y CAT, right hind mass; fungal elements seen         |
| Exophiala xenobiotica (2) | MALDI-ToF MS of isolate | Fluid, Hand                  | M 88y, infected ganglion                                  |
| Exophiala xenobiotica (3) | Panfungal PCR of tissue | Tissue biopsy                | M 69, large mass on arm                                  |
| Exserohilum rostratum  | Phenotypic ID of isolate | Nasal tissue                 | M 50y, right nasal fungal mass                            |
| Falciformispora tompkinsii | rDNA sequencing of isolate | Tissue biopsy                | M 62y, phaeohyphomycosis of leg; confirmed by PCR of tissue, serum BDG +ve |
| Fonsecaea monophora (1) | rDNA sequencing of isolate | Tissue biopsy                | M 74y, wrist lesion                                       |
| Fonsecaea monophora (2) | rDNA sequencing of isolate | Skin biopsy                  | M 59y, chromoblastomycosis, lesions > 20 y; histology positive|
| Fusarium oxysporum *    | Panfungal PCR of fluid   | Knee fluid                   | F 25y, joint infection/ haematoma (knee); PCR positive for same organism 2 months later |
| Fusarium solani *       | Phenotypic ID of isolate | Tissue biopsy                | M 47y, eumycetoma, foreign body removal; isolated twice   |
| Organism (Case Number) | Identification Method | Site | Clinical Presentation |
|------------------------|-----------------------|------|----------------------|
| **Kirschsteiniothelia rostrata** | MALDI-ToF MS of isolate | Tissue biopsy | M 82y, fungal abscess, foot; isolated 4 times over 4 months, fungal elements seen on each occasion |
| **Leptospora sp.** | Panfungal PCR of fluid | Synovial fluid | F 56y, joint infection, swollen knee |
| **Madurella mycetomatis (1)** | Panfungal PCR of tissue | Finger biopsy | F 28y, black grain eumycetoma; grains seen in tissue, PCR +ve on second sample |
| **Madurella mycetomatis (2)** | Panfungal PCR of tissue | Foot tissue | M 30y, chronic eumycetoma of foot; black grains seen |
| **Madurella mycetomatis (3)** | MALDI-ToF MS of isolate | Foot biopsy | M 50y, eumycetoma of foot, previous penetrating injury, Sudan |
| **M. pseudomycetomatis (1)** | rDNA sequencing of isolate | Foot tissue | F 67y, eumycetoma of foot 18 months, previous renal transplant |
| **M. pseudomycetomatis (2)** | MALDI-ToF MS of isolate | Foot tissue | U 27y, eumycetoma surgically resected |
| **Medicopsis romeroi (1)** | MALDI-ToF MS of isolate | Foot tissue | M 60y, dark grain eumycetoma; isolated twice over 3 months |
| **Medicopsis romeroi (2)** | MALDI-ToF MS of isolate | Skin biopsy | M 68y, immunocompromised with foot "ulcer" |
| **Medicopsis romeroi (4)** | MALDI-ToF MS of isolate | Arm tissue | M 35y, arm lesion, post renal transplant |
| **Medicopsis romeroi (5)** | Panfungal PCR of tissue | Toe tissue | M 59y, soft tissue infection, post renal transplant |
| **Medicopsis romeroi (6)** | Panfungal PCR of tissue | Tissue/fluid | F 62y, no additional details given |
| **Microascus marinus** | rDNA sequencing of isolate | Biopsy, sole of foot. | M 58y, foot lesion; isolated twice |
| **Ochroconis tsunayotschae** | rDNA sequencing of isolate | Eye | M 57y, Corneal infection |
| **Parathyridaria percutanea (1)** | Panfungal PCR of tissue | Tissue biopsy | F 31y, skin nodules, renal transplant patient; pigmented fungal elements seen on histology |
| **Parathyridaria percutanea (2)** | Panfungal PCR of tissue | Tissue, leg | F 50y, nodules knees and feet for 4 months; ex-Somalia, BDG +ve, Previous liver transplant, confirmed by isolation of organism |
| **Phaeoacremonium spp.** | Phenotypic ID of isolate | Fluid, Toe and knee | M 63y, cystic lesions on toes, knee infection; isolated x5 over 6 month period |
| **Ph. parasiticum** | MALDI-ToF MS of isolate | Tissue foot | M 52y, mass forefoot > 2 yrs |
| **Ph. rubrigenum (1)** | MALDI-ToF MS of isolate | Aspirate, finger | F 71y, lesion index finger, renal transplant; isolated twice over 6 month period |
| **Ph. rubrigenum (2)** | MALDI-ToF MS of isolate | Tissue biopsy | M 57y, thigh lesion, renal transplant; isolated x3 over 5 months |
| **Phaeoisaria clematidis** | rDNA sequencing of isolate | Tissue biopsy | M 46y, Abscess in arm; Nigerian |
| **Phialocephala curvata** | MALDI-ToF MS of isolate | Tissue, foot | M 68y, nodule on foot, post renal transplant; confirmed by PCR of tissue, histology positive, Travel to Nigeria |
| **Pleistotheca clematidia** | MALDI-ToF MS of isolate | Tissue biopsy | M 32y, unwell post tissue expanders |
| **Pseudallescheria elliottoides** | MALDI-ToF MS of isolate | Tissue biopsy | M 41y, chronic Achilles abscess |
| **Rhytidhidystrom rufulum** | Panfungal PCR of tissue | Tissue biopsy | M 33y, lump right ankle, suspect mycetoma; isolate also recovered |
| **Sarocladium bactrocephalum** | rDNA sequencing of isolate | Tissue biopsy | M 54y, joint infection |
| **Sced. apiospermum (1)** | MALDI-ToF MS of isolate | Fluid, finger | F 89y, index finger flexor sheath abscess |
| **Sced. apiospermum (2)** | MALDI-ToF MS of isolate | Fluid, joint | F 74y, septic arthritis |
| **Sced. apiospermum (3)** | MALDI-ToF MS of isolate | Fluid, knee | F 75y, intrapatellar bursitis |
| **Sced. apiospermum (4)** | MALDI-ToF MS of isolate | Tissue biopsy | F 68y, cellulitis forearm, post renal transplant |
| **Sced. apiospermum (5)** | MALDI-ToF MS of isolate | Tissue swab | M 70y, enlarging sore after gardening wound |
Table 2. Cont.

| Organism (Case Number) | Identification Method | Site | Clinical Presentation |
|------------------------|-----------------------|-----|-----------------------|
| *Sced. apiospermum* (6) | MALDI-ToF MS of isolate | Tissue, forearm | M 68y, multiple abscesses forearm, glioblastoma |
| *Sced. apiospermum* (7) | MALDI-ToF MS of isolate | Tissue, leg | M 83y, cellulitis right leg |
| *Sced. apiospermum* (8) | MALDI-ToF MS of isolate | Tissue, hand | M 76y, Right hand wound, AML; isolated twice over 3 weeks |
| *Sced. apiospermum* (9) | MALDI-ToF MS of isolate | Tissue, thigh | F 71y, thigh lesion |
| *Sced. apiospermum* (10) | MALDI-ToF MS of isolate | Tissue, wrist | F 60y, dorsal wrist mass and synovitis > 2 yrs |
| *Sced. apiospermum* (11) | MALDI-ToF MS of isolate | Corneal scrape | F 40y, fungal keratitis |
| *Sced. apiospermum* (12) | MALDI-ToF MS of isolate | Corneal scrape | F 65y, superficial fungal keratitis |
| *Sced. apiospermum* (13) | MALDI-ToF MS of isolate | Eye | M 63y, no additional clinical details provided |
| *Scedosporium aurantiacum* | MALDI-ToF MS of isolate | Tissue, ankle | F 63y, fungal mass, wound rotten wood; isolated twice over 7 d |
| *Scedosporium de hoogii* (1) | MALDI-ToF MS of isolate | Aspirate, wrist | M 81y, infected wrist joint, "low immunity" |
| *Scedosporium de hoogii* (2) | MALDI-ToF MS of isolate | Corneal scrape | F 67y, fungal keratitis with corneal ulcer |
| *Sporothrix brasiliensis* | rDNA sequencing of isolate | Pus | M 28y, skin lesions/ulcers after cat scratch; Brazilian cat imported into UK, histology positive |

Bold isolates are proven infections; * denotes identification to species complex level. BDG = serum β-D-Glucan test. For isolates identified by rDNA sequencing, generated sequences matched the following GenBank accession numbers with the given % identity: *Cladophialophora boppii* (HQ114280; 100%); *Falciformispora tompkinsii* (NR_132041; >98.5%); *Fonsecaea monophora* (LC317599; >98.5%); *Madurella pseudomycetomatis* (MK926823; >99%); *Microascus murinus* (MH871664; 99%); *Ochroconis tshawytschae* (MH870422; 99%); *Phaeoisaria clematidis* (MW131990; >97.5%); *Sarcocystis bactrocephalum* (MH859409; 98.5%); *Sporothrix brasiliensis* (MH877527; 100%).

Since successful treatment of cases of subcutaneous mycoses most frequently relies upon a combination of surgical intervention and often protracted antifungal therapy, antifungal susceptibility testing of the causative agent (if isolated in culture) is an important component of antifungal management in individual cases. In addition, the generation of antifungal susceptibility profile databases permits predictions of susceptibility/resistance in future cases involving the same species that are refractory to culture. Table 3 presents the antifungal susceptibility profiles of the *non-Alternaria* species isolated from subcutaneous infections during the period 2016–2022. The range of antifungal agents tested with each isolate was largely determined by the requesting physician and was further tailored to be appropriate for the type/site of infection. For example, isolates from cases of ocular infection (keratitis) were tested against additional topical antifungal agents that would be appropriate for the treatment of such presentations (natamycin, econazole).

Table 3. MIC values for 50 *non-Alternaria* species.

| Organism | MIC (mg/L) |
|----------|------------|
|          | AMB | VRC | ITC | PSC | AND | NAT | OTHER |
| *Cladophialophora boppii* | 1   | 0.5 | nd  | nd  | nd  | 4   | -     |
| *Curvularia sp.* | 0.25 | 1   | 0.25 | nd  | nd  | 1   | -     |
| *Curvularia hawaiiensis* | 0.125 | 0.5 | nd  | 0.06 | nd  | nd  | -     |
| *Emarellia grisea* | 0.5 | 0.125 | 0.25 | 0.25 | nd  | nd  | -     |
| *Exophiala campbellii* | 0.5 | 0.125 | 0.25 | 0.25 | <0.015 | nd  | -     |
| *Exophiala jeanselmei* | 1   | 0.25 | 0.25 | nd  | nd  | nd  | -     |
| *Exophiala lecanii-corni* | 1   | 0.25 | 0.5 | 0.25 | nd  | nd  | ISC = 2 |
| *Exophiala oligosperma* | 1   | 0.5 | 0.5 | 0.06 | 0.06 | nd  | nd    |
| *Exophiala xenobiotica* (1) | 0.5 | 4   | 0.25 | nd  | nd  | nd  | -     |
| *Exophiala xenobiotica* (2) | 0.25 | 0.25 | 0.25 | nd  | nd  | nd  | -     |
| *Exserohilum rostratum* | 0.25 | 1   | 0.5 | nd  | 0.06 | nd  | -     |
### Table 3. Cont.

| Organism                        | AMB | VRC | ITC | PSC | AND | NAT | OTHER |
|---------------------------------|-----|-----|-----|-----|-----|-----|-------|
| Fonsecaea monomorpha            | 0.5 | 0.06| 0.25| 0.06| nd  | nd  | ISC = 0.06 |
| Fusarium solani                 | 4   | 4   | >16 | nd  | nd  | nd  | -     |
| Kirschsteiniothelia rostrata    | 1   | 0.06| 0.25| 0.06| <0.015| nd  | ISC = 0.25 |
| Madurella mycetomatis           | 0.125| 0.25| 0.125| nd  | 4   | nd  | -     |
| Madurella pseudomycetomatis     | 0.125| 0.125| 0.25| 0.06| 4   | nd  | -     |
| Medicopsis romeroi (1)           | 1   | 0.25| 1   | nd  | 0.5 | nd  | -     |
| Medicopsis romeroi (2)           | 0.5 | 2   | 1   | 1   | 2   | nd  | TRB = 0.125 |
| Medicopsis romeroi (3)           | 0.5 | 0.125| 0.06| 0.06| nd  | nd  | ISC = 0.25 |
| Medicopsis romeroi (4)           | nd  | 1   | >16 | 0.25| nd  | TRB = 0.06 |
| Microascus murinus              | 0.5 | 8   | 0.5 | nd  | 0.5 | nd  | -     |
| Parathyridaria percutanea        | 0.25| 2   | >16 | nd  | 2   | nd  | -     |
| Phaeoacremonium spp.            | 0.5 | 0.125| 4   | nd  | 8   | nd  | -     |
| Phaeoacremonium rubrigenum (1)   | 0.5 | 0.125| 1   | nd  | nd  | 2   | -     |
| Phaeoacremonium rubrigenum (2)   | 1   | 0.25| 0.5  | 0.25| nd  | nd  | ISC = 1 |
| Phaeoacremonium parasiticum      | 1   | 0.5 | >16 | 0.5 | 8   | nd  | ISC = 0.5 |
| Phaeoisaria clematidis           | 0.5 | 0.06| 0.25| 0.06| 0.125| nd  | TRB = 0.125 |
| Phialemonopsis curvata           | nd  | 0.5 | 1   | 0.5 | nd  | nd  | -     |
| Plectosphaerella cucumerina      | 0.5 | 2   | 0.5 | nd  | nd  | nd  | -     |
| Pseudallescheria elliptoeidea    | nd  | nd  | 0.5 | nd  | nd  | nd  | NYT = 4 |
| Rhizidiasteron rufalum           | 0.5 | 0.25| 0.06| <0.03| nd  | nd  | -     |
| Sarocladium bactrocephalum       | 0.125| 0.125| 0.25| nd  | 4   | nd  | -     |
| Scedosporium apiospermum (1)     | 1   | 0.5 | 4   | nd  | 2   | nd  | -     |
| Scedosporium apiospermum (2)     | 4   | 0.5 | 1   | nd  | nd  | nd  | -     |
| Scedosporium apiospermum (3)     | 4   | 0.25| 0.25| nd  | nd  | nd  | -     |
| Scedosporium apiospermum (4)     | 2   | 0.5 | 1   | nd  | nd  | TRB = >16 |
| Scedosporium apiospermum (5)     | 4   | 0.5 | 0.5 | 0.5 | nd  | nd  | -     |
| Scedosporium apiospermum (6)     | 4   | 1   | 2   | 2   | nd  | nd  | -     |
| Scedosporium apiospermum (7)     | 0.5 | 0.125| 0.5 | nd  | nd  | nd  | -     |
| Scedosporium apiospermum (8)     | 2   | 0.5 | 2   | 0.5 | nd  | nd  | -     |
| Scedosporium apiospermum (9)     | 4   | 0.125| 0.25| nd  | nd  | nd  | -     |
| Scedosporium apiospermum (10)    | 1   | 0.5 | 1   | nd  | nd  | nd  | -     |
| Scedosporium apiospermum (11)    | 2   | 0.5 | nd  | nd  | nd  | 2   | -     |
| Scedosporium apiospermum (12)    | 4   | 0.5 | 4   | nd  | nd  | 4   | ECZ = 2 |
| Scedosporium apiospermum (13)    | 2   | 0.5 | 0.5 | nd  | nd  | 2   | ECZ = 0.5 |
| Scedosporium aurantiaconum       | 16  | 0.5 | 2   | 0.5 | nd  | nd  | -     |
| Scedosporium de hougui (1)       | 8   | 0.25| 1   | 1   | 8   | nd  | -     |
| Scedosporium de hougui (2)       | 2   | 0.25| 0.5 | nd  | 2   | nd  | -     |
| Sporothrix brasiliensis          | 0.5 | 16  | 0.5 | 0.5 | nd  | ISc = 4 |

**Abbreviations:** nd = not done; AMB = amphotericin B; VRC = voriconazole; ITC = itraconazole; PSC = posaconazole; AND = anidulafungin; NAT = natamycin; TRB = terbinafine; ISC = isavuconazole; ECZ = econazole; NYT = nystatin.

As there are no validated breakpoint interpretations for any of the antifungal agents for any of the isolates documented, we have loosely applied those epidemiological cut-off values and clinical breakpoints established for *Aspergillus fumigatus*, when available. These are: amphotericin B, itraconazole, voriconazole and isavuconazole ≤ 1.0 mg/L susceptible.
and >2.0 mg/L resistant, posaconazole ≤0.125 mg/L susceptible and >0.25 mg/L resistant. There are no validated anidulafungin breakpoints for moulds and the MICs against most of the moulds tested, with some notable exceptions, appear to be quite elevated. Terbinafine is usually used to treat dermatophyte infections and does not have validated breakpoints; for the treatment of moulds other than dermatophytes, for example in the treatment of highly refractory *Lomentospora prolificans* infections, it is usually only used in combination with voriconazole with which it demonstrates synergistic activity. As can be seen from the antifungal susceptibility data presented in Table 3, with the exception of *Fusarium solani* and some isolates of *Medicago romeroi*, when applying these breakpoints most organisms were susceptible to at least one of the triazole antifungals (itraconazole, posaconazole, voriconazole, isavuconazole) in vitro. However, no single triazole antifungal agent exhibited activity across the whole spectrum of organisms isolated from subcutaneous infections, underscoring the importance of accurate identification and susceptibility testing of individual isolates.

By far the most common agent of subcutaneous infections retrieved in our LIMS searches were organisms in the genus *Alternaria*. A total of 42 cases were retained after consolidation of the three separate searches performed, corresponding to subcutaneous masses in domestic companion animals (n = 26), subcutaneous nodules in humans (n = 11), 6 of which were organ transplant recipients, and an additional 5 cases of fungal keratitis in humans (Table 1). Full details of clinical presentation and method of diagnosis are presented in Table 4.

Table 4. Clinical details and diagnosis method for the 42 cases of subcutaneous infection and keratitis caused by *Alternaria* spp.

| Case (Year) | ID | Site | Clinical Presentation |
|-------------|----|------|----------------------|
| Isolates recovered from clinical material and susceptibility testing was requested/performed: | | | |
| 1 (2016) | PT | Tissue, knee | M 66y, right knee lesion following renal transplant |
| 2 (2017) | rD | Tissue, thigh | M 57y, lesion right thigh following hand transplant |
| 3 (2017) | MT | Tissue | M 66y, subcutaneous phaeohyphomycotic cyst |
| 4 (2020) | MT | Tissue, thigh | M 69y, purple nodule on right thigh |
| 5 (2019) | MT | Tissue, knee | F 36y, left knee ulcer following renal transplant |
| 6 (2018) | PT | Corneal scrape | F 23y, fungal keratitis |
| 7 (2020) | PT | Corneal scrape | M 52y, fungal keratitis |
| 8 (2018) | PT | Corneal scrape | F 66y, fungal keratitis |
| 9 (2020) | MT | Tissue, nose | F, CAT, dermatitis on nose, fungal elements seen |
| 10 (2017) | PT | Tissue, ear | F, CAT, fungal granuloma excised from ear pinna, fungal elements seen |
| 11 (2020) | PT | Tissue | M, CAT, recurrent pyogranulomatous dermatitis with abundant fungal elements |
| | | | Confirmed by PCR on tissue |
| Isolates recovered from clinical material but susceptibility testing was not requested: | | | |
| 12 (2020) | PT | Skin biopsy | F, DOG, multiple skin nodules |
| 13 (2021) | rD | Tissue | F 67y, no clinical details provided |
| 14 (2019) | PT | Corneal scrape | M 59y, corneal graft following chemical injury |
| 15 (2021) | MT | Corneal scrape | M 59y, keratitis following corneal abrasion |
| 16 (2019) | PT | Tissue biopsy | U, CAT, Fungal mycetoma |
| 17 (2019) | PT | Tissue biopsy | M, CAT, cutaneous fungal granuloma on nose |
| 18 (2021) | PT | Tissue biopsy | M 4y, CAT, swollen nose, fungal elements seen |
| 19 (2021) | PT | Tissue biopsy | F 6y, CAT. Ulcerated nodule nose, fungal elements seen |
Table 4. Cont.

| Case (Year) | ID   | Site               | Clinical Presentation                                                                 |
|------------|------|--------------------|---------------------------------------------------------------------------------------|
| 20 (2016)  | PT   | Tissue biopsy      | M CAT, nasal mass, fungal elements seen                                                |
| 21 (2017)  | PT   | Tissue, nose       | M, CAT, fungal granuloma on nose, fungal elements seen                                  |
|            |      |                    | Independent isolation from second biopsy                                               |
| 22 (2018)  | PT   | Tissue, nose       | M, CAT, nasal mass, fungal elements seen                                               |
| 23 (2020)  | PT   | Tissue, nose       | U, CAT, fungal granuloma on nose                                                       |
| 24 (2017)  | PT/rD| Tissue, leg        | F, DOG, immunosuppressed, multifocal abscesses on legs and paws, Phaeohyphomycosis on histology. Confirmed by direct PCR on tissue, two further independent isolations, direct microscopy positive on all samples |
| 25 (2017)  | rD   | Tissue, nose       | M, CAT, fungal mass bridge of nose, fungal elements seen on histology and direct examination of tissue |
| 26 (2019)  | PT   | Tissue, foot       | M, CAT, metatarsal and digital lesions, fungal elements seen on direct examination      |
| 27 (2017)  | PT   | Tissue             | M, CAT, fungal mass, mycotic granuloma on histology, fungal elements seen on direct examination |
|            |      |                    | Diagnosis made solely by panfungal PCR of tissue (no isolate was recovered for further analyses): |
| 28 (2020)  | PCR  | Tissue, thigh      | M 59y, thigh lesion following renal transplant                                         |
| 29 (2019)  | PCR  | Skin Biopsy        | U, 57y, no clinical details provided                                                   |
| 30 (2016)  | PCR  | Tissue, leg        | M 39y, leg lesion following renal transplant                                            |
| 31 (2018)  | PCR  | Tissue Biopsy      | F 61y, granulomatous fungal folliculitis post-transplant                                |
| 32 (2017)  | PCR  | Skin biopsy        | M 64y, Crohns, purple ulcerated papules following rose thorn injury                    |
| 33 (2016)  | PCR  | Tissue             | M, CAT, no clinical details provided                                                   |
| 34 (2017)  | PCR  | Tissue, nose       | M, CAT, no clinical details provided                                                   |
| 35 (2018)  | PCR  | Tissue, foot       | M, CAT, solitary cutaneous mass on paw, histology-confirmed fungal granuloma           |
| 36 (2020)  | PCR  | Tissue, nose       | M, CAT, nasal mass >2yrs, recurred post-antifungal treatment (itraconazole)            |
| 37 (2020)  | PCR  | Punch biopsy       | M, CAT, no clinical details provided. Repeat PCR positive on separate sample            |
| 38 (2020)  | PCR  | Biopsy, ear        | M, DOG, mass left pinna                                                                 |
| 39 (2020)  | PCR  | Biopsy             | M 5y, CAT, no clinical details provided                                                |
| 40 (2020)  | PCR  | Biopsy, nose       | M 11y, CAT, cutaneous fungal granuloma on muzzle                                       |
| 41 (2021)  | PCR  | Biopsy, nose       | M 11y, DOG, nose mass, mycotic granuloma associated with foreign material              |
| 42 (2021)  | PCR  | Biopsy, nose       | M 9y, CAT, nasal mass                                                                  |

ID = identification/diagnosis method; MT = MALDI-ToF MS of isolates; PT = phenotypic identification of isolate; rD = rDNA sequencing of isolate; PCR = panfungal PCR of tissue. For isolates identified by rDNA sequencing, individual sequences matched sequences corresponding to a variety of “Alternaria sp.” in GenBank, always with >98.5% sequence identity.

When agents are used topically such as in the treatment of mycotic keratitis, different higher breakpoints may be more applicable, as immediately after topical application concentrations of the antifungal agent should be greatly in excess of the MIC of the drug for the infecting organism. The three agents we tested that can be used topically for this indication are amphotericin B, available as a 0.15% solution (1500 mg/L) and voriconazole and natamycin, available as 1% solutions (10,000 mg/L). However, the duration that this localized concentration is maintained and penetration of the drug into tissue will impact on activity, so the validation of breakpoints in this setting has not been addressed.

As seen with infections due to the other agents of subcutaneous mycosis discussed above, there was an obvious sex bias in the human cases of traumatic Alternaria infection (9 infections in males, 5 in females [1 unknown sex]; 64% males), and again the majority...
of infections (13/16; 81%) were diagnosed in individuals >50 years of age. A similar sex bias was also observed in Alternaria spp. infections in animals (19 male: 6 female; 1 unknown; 76% male). Six of the 16 subcutaneous human infections occurred in post-solid organ transplant patients (four post-renal transplant, one post-hand transplantation, one organ not specified; Table 4), and were known to affect the extremities (predominantly the legs), in keeping with the usual sites of traumatic injury. Similarly, where stated, all Alternaria infections in domestic cats and dogs involved body sites likely to be prone to inoculation injuries (nose, ears, paws and legs), and in many cases (15/26) were confirmed by direct visualization of fungal elements in biopsy samples or histology, repeat isolation from independent samples, PCR-driven diagnosis or a combination of the above.

The antifungal susceptibility profiles for the 12 Alternaria sp. isolates that were recovered in culture (cases 1–12 in Table 4) are shown in Table 5. The apparent relatively low rate of recovery of Alternaria spp. isolates (12 isolates from 42 cases) is a reflection of the sample types that were received in many cases, where clinical material was submitted after previous formalin fixation, or as wax curls from histological blocks, thus preventing attempts at culture. In most cases, examination of material by direct microscopy at the MRL, or histology reports that accompanied the samples revealed or reported fungal elements consistent with the final diagnosis, making it unlikely that these molecular diagnoses were detecting fungal contaminants rather than the true pathogen (data not shown). Based on epidemiological cut-off values and clinical breakpoints established for Aspergillus fumigatus, all isolates tested were susceptible to amphotericin B, itraconazole and anidulafungin (although only three isolates were tested with anidulafungin), and the majority had relatively low MIC values with posaconazole. However, voriconazole activity was severely reduced against all except two of the isolates, with MIC values that would be interpreted as intermediate (2 and 4 mg/L) or resistant (8 mg/L or above) based on A. fumigatus breakpoints. Similarly, although only three isolates were tested against isavuconazole, all three exhibited elevated MICs that would be above the usual range seen with A. fumigatus. This reduced in vitro susceptibility to voriconazole is not unique to Alternaria sp. isolates from subcutaneous infections, based on historically collated MRL antifungal susceptibility data, which demonstrated that 25/33 (76%) isolates from environmental or other sources would be classed as intermediate/resistant to voriconazole in vitro (data not shown).

Table 5. Antifungal MIC profiles for the Alternaria isolates 1–12 from Table 4. Antifungal drug abbreviations are as described in Table 3.

| Isolate Number | MIC (mg/L) |
|----------------|------------|
|                | AMB | ITC | VRC | PSC | ISC | AND | TRB | NAT |
| 1              | 0.25 | 0.5 | 4   | 0.06 | 4   | <0.015 | 0.25 | 2   |
| 2              | 0.25 | 0.5 | 8   | 0.06 | 16  | <0.015 | 4     | nd  |
| 3              | 0.5  | 0.5 | <0.03 | 0.25 | nd  | nd   | 4     | nd  |
| 4              | 0.5  | 0.25 | 2   | 0.125 | nd  | 0.125 | nd   | nd  |
| 5              | 0.5  | 0.5 | 16  | 0.5  | 16  | nd   | 0.5   | nd  |
| 6              | 0.5  | 0.25 | 0.5 | nd  | nd  | nd   | nd   | nd  |
| 7              | 0.25 | 0.5 | 2   | 0.25 | nd  | nd   | nd   | 2   |
| 8              | 1    | 1    | 8   | 0.25 | nd  | nd   | nd   | 2   |
| 9              | 0.5  | 0.5 | 8   | nd  | nd  | nd   | nd   | nd  |
| 10             | 0.5  | 0.25 | 8   | nd  | nd  | nd   | nd   | nd  |
| 11             | nd   | 0.25 | 4   | nd  | nd  | nd   | nd   | nd  |
| 12             | nd   | 0.5  | nd  | nd  | nd  | nd   | 0.125 | nd  |
4. Discussion

Here, we have retrospectively searched the MRL LIMS to retrieve all possible cases of subcutaneous fungal infections and traumatic keratitis diagnosed at the laboratory between October 2016 and February 2022. Of the 105 cases recovered, 42 concerned *Alternaria* spp. (Table 1) with over 60% (n = 26) of those presenting as subcutaneous masses of the extremities in domestic companion animals, and a further 11 similar cases in humans (plus 5 cases of fungal keratitis). The preponderance of members of this genus as etiological agents of such infections probably reflects both its ubiquitous nature, and the fact that it is a common plant pathogen likely present on many hard or thorny materials on which humans and pets might injure themselves [29,30]. Indeed, subcutaneous infections with *Alternaria* species in humans and domestic animals have been reported extensively in the literature previously; in humans there is a clear association with previous solid organ transplantation [14,18,25,31–34]. This same pattern is reflected in the cases retrieved during this study: 6 of 11 human infections were in patients who had previously received solid organ transplants (Tables 1 and 4). A substantial proportion of the *Alternaria* sp. isolates reported here displayed elevated in vitro MICs with voriconazole that would be indicative of resistance (5/11 isolates with MICs of 8 mg/L or higher: Table 5). Our own anecdotal evidence suggests that these elevated MICs with *Alternaria* and voriconazole might have clinical relevance, since we have been involved in the management of several cases of subcutaneous alternariosis that have failed to respond or progressed despite protracted voriconazole therapy and persistently therapeutic antifungal drug levels (AMB and EM), unpublished observations. Indeed, several published case reports of breakthrough/refractory *Alternaria* infections that occurred during voriconazole therapy would support this contention [33,35–37], as would individual studies reporting limited in vitro voriconazole activity against members of this genus [34,38]. However, cases of successful treatment of primary cutaneous *Alternaria* infections with voriconazole have also been reported [39], highlighting the importance of antifungal susceptibility testing of individual isolates to optimize therapeutic strategies. Additionally, it is possible that differences in MICs reported here and elsewhere [34,38] between individual *Alternaria* isolates could reflect species-specific differences in susceptibility. Effectively, *Alternaria* is a large and pleomorphic genus that comprises approximately 300 species separated into at least 25 taxonomic sections [40–43] with polyphasic approaches, including multi-locus sequence typing required for accurate identification to species level. Most published cases of human infections (including the present study) did not attempt such precise identification. Indeed, where molecular approaches were used to confirm identification of the isolates presented here, analyses were only sufficient to suggest that the majority of isolates likely belonged to *Alternaria Section Infectoriae* [42].

The 64 cases of infections of implantation that did not implicate *Alternaria* spp. involved an additional 38 species comprising 25 genera of ascomycetes, all of which have previously been reported as etiological agents of subcutaneous fungal infections or traumatic keratitis in humans (Table 1). The genera *Exophiala* (9 cases), *Madurella* (5 cases), *Medicopsis* (6 cases) and *Scedosporium* (16 cases), all of which have been frequently associated with subcutaneous fungal infection or genuine eumycetoma [5–9,13,16–18,20,23,25–28], predominated. Antifungal susceptibility profiles for the causative organisms again revealed variable susceptibility to amphotericin B and the most commonly employed systemic azole antifungal drugs (Table 3), again highlighting the importance of correct isolate identification and susceptibility testing of individual isolates in optimising patient management. Oralazole therapy is the preferred option in these patients wherever possible, as prolonged courses are often required. Together with the 6 cases of subcutaneous *Alternaria* spp. infection in organ transplant recipients, subcutaneous infections with other organism were identified in a further 8 solid organ transplant patients (7 renal transplant; 1 liver transplant). The responsible organisms were again varied and included *Madurella mycetomatis* (1), *Medicopsis romeroi* (2), *Parathyridaria percutanea* (2), *Phaeoacremonium rubrigenum* (2) and *Phialemoniopsis curvata* (1). According to the accompanying clinical details (where available),
none of the 14 cases of subcutaneous infections in organ transplant recipients had evidence of previous infection at the affected body sites, nor were these cases of relapses of previously treated infections post-transplantation. Moreover, none of the patients had signs or symptoms of likely disseminated infection from a different primary site. These observations have several intriguing implications. First, several of the organisms reported here from subcutaneous infections in transplant patients are known agents of eumycetoma [12,13], and yet the clinical features of infections were more typical of phaeohyphomycosis or locally invasive fungal infection rather than genuine eumycetoma, due to the lack of draining sinuses, extensive tumefaction or production of fungal grains (see cases 3, 4 and 5 involving *Medicopsis romeroi*, Table 2). This suggests that the typical clinical presentation associated with subcutaneous fungal infections is likely to be determined also by the immunological status of the host rather than only by the etiological agent involved. Second, they imply that many of these infections diagnosed several years post-transplantation have arisen from subcutaneous fungal elements introduced during historical minor injuries that have remained latent and subclinical for many years until later immunosuppression. This concept is not entirely novel as several studies have reported re-activation of dimorphic fungal infection many years after initial exposure [43–45], immunological and epidemiological evidence has been presented in support of dormant cryptococcal infection [46] and anecdotal reports have described recurrence of previously treated infections following transplantation [47]. Since survival inside macrophages or formation of granuloma have been proposed to be prerequisites for fungal latency, it is perhaps not surprising that ubiquitous saprobes accidentally implanted into the sub-dermis (with subsequent granulomatous reactions) may also have the capacity to persist in inert form for many years in immunocompetent hosts. In this regard the dematiaceous nature of many of the agents identified is significant as the production of melanin in the cell wall has long been recognized as a putative virulence factor enhancing the survival of fungal cells within the host phagocytes [48–50]. While the bias towards male sex in subcutaneous fungal infections has previously been proposed to result from increased likelihood of engaging in physical outdoor work, the bias towards older age as reported here would also be in keeping with the idea that such infections may remain latent or clinically innocuous for many years.

There are several limitations to the current study. It is unfortunate that for many of the cases described here, detailed history of previous trauma, occupation of the patients and geographical area of likely acquisition are lacking. In addition, for many of the solid organ transplantation patients, data concerning delay between transplantation and onset of clinical presentation and the nature and duration of immunosuppressive agents employed was lacking. In part, this reflects the nature of national reference laboratory work, which is based on patient/case referrals with limited direct access to patient data or the ability to seek additional clinical information. However, it is also a likely reflection of the fact that many subcutaneous infections present clinically many years after initial acquisition, following relatively minor or innocuous traumas that the patient does not recollect. This situation is probably aggravated in those cases that follow later solid organ transplantation, where an inoculated organism has remained inert/subclinical for many years. It is also unfortunate that for most of the cases, we cannot be certain that organisms submitted to antifungal susceptibility testing were from patients that were antifungal treatment naïve. However, given that these isolates were either referred to our laboratory from diagnostic biopsy specimens, or cultured from them here at the MRL, it is likely that the majority of these cases represent the initial presentation/diagnosis and that the patients had not received prior antifungal treatment (with the exception of the relapsed cases of *E. grisea* and *M. romeroi* (case 1) infection (Table 2).

In summary, here we have presented over 5 years of data concerning fungal infections of implantation (subcutaneous fungal infections and traumatic fungal keratitis) referred to the UK MRL, together with antifungal susceptibility profiles of the causative agents, where available. While a wide array of fungal species and genera were implicated in such infections, a select few (*Alternaria* spp., *Exophiala* spp., *Madurella* spp., *Medicopsis romeroi*...
and Scedosporium spp.) predominated. Further studies will be required to explain the preponderance of these select organisms in subcutaneous infections in general and those affecting solid organ transplant recipients in particular. It is possible that this simply reflects their relatively high abundance in nature in environments frequented by humans, or a predilection for particularly thorny plant species. However, it also remains possible that certain species possess particular virulence factors that permit their immune evasion, prolonged survival/latency post-inoculation and the capacity to re-activate many years later if host immunity wanes due to immunosuppression or advancing years.

**Author Contributions:** Conceptualisation, A.M.B. and E.M.J.; data generation, M.F., Z.P., C.J.L. and M.P.; data curation, A.M.B. and C.J.L.; writing—original draft preparation, A.M.B.; writing—review and editing, A.M.B., M.F., Z.P., C.J.L., M.P. and E.M.J. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Ethical review and approval was waived for this study, due to the fact that no patients were identified and all tests were part of normal diagnostic workup.

**Informed Consent Statement:** Patient consent was waived due to none of the patients being identifiable from the data included.

**Data Availability Statement:** No data were reported in this study.

**Acknowledgments:** We are grateful to Sigma Chemical Co., St. Louis, MO, USA, Basilea Pharmaceuticals Ltd., Basel, Switzerland, Pfizer Central Research, Sandwich, UK, Janssen Research Foundation, Beerse, Belgium and Merck, Sharp and Dohme, Hoddesdon, UK, for supplying antifungal agents for antifungal susceptibility testing. We also thank the other members of the MRL for their assistance in routine mould susceptibility testing, processing of clinical samples and identification of mould isolates, and the various clinical and veterinary laboratories across the UK for submitting their isolates and samples of interest.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Sutton, D.A.; Rinaldi, M.M.; Sanche, S.E. Dematiaceous fungi. In *Clinical Mycology*, 2nd ed.; Anaisse, E.J., McGinnis, M.R., Pfaffer, M.A., Eds.; Churchill Livingstone: London, UK, 2009; pp. 329–354.
2. Queiroz-Telles, F. Chromoblastomycosis: A neglected tropical disease. *Rev. Inst. Med. Trop. Sao Paulo* 2015, 57, 46–50. [CrossRef] [PubMed]
3. Arcobello, J.T.; Revankar, S.G. Phaeohyphomycosis. *Semin. Respir. Crit. Care Med.* 2020, 41, 131–140. [CrossRef] [PubMed]
4. Guégan, S.; Lanternier, F.; Rouzaud, C.; Dupin, N.; Lortholary, O. Fungal skin and soft tissue infections. *Curr. Opin. Infect. Dis.* 2016, 29, 124–130. [CrossRef] [PubMed]
5. Seyedmousavi, S.; Guillot, J.; de Hoog, G.S. Phaeohyphomycoses, emerging opportunistic diseases in animals. *Clin. Microbiol. Rev.* 2013, 26, 19–35. [CrossRef] [PubMed]
6. Overy, D.P.; Martin, C.; Muckle, A.; Lund, L.; Wood, J.; Hanna, P. Cutaneous Phaeohyphomycosis caused by *Exophiala attenuata* in a domestic cat. *Mycopathologia* 2015, 180, 281–287. [CrossRef] [PubMed]
7. Lieberman, J.A.; Fiorito, J.; Ichikawa, D.; Fang, F.C.; Rakita, R.M.; Bourassa, L. Long-term carriage of *Medicopsis romeroi*, an agent of black-grain mycetoma, presenting as phaeohyphomycosis in a renal transplant patient. *Mycopathologia* 2019, 184, 671–676. [CrossRef]
8. Isa-Isa, R.; Garcia, C.; Isa, M.; Arenas, R. Subcutaneous phaeohyphomycosis (mycotic cyst) *Clin. Dermatol.* 2012, 30, 425–431.
9. Abdolrasouli, A.; Gonzalo, X.; Jatan, A.; McArthur, G.J.; Francis, N.; Azadian, B.S.; Borman, A.M.; Johnson, E.M. Subcutaneous phaeohyphomycosis cyst associated with *Medicopsis romeroi* in an immunocompromised host. *Mycopathologia* 2016, 181, 717–721. [CrossRef]
10. Queiroz-Telles, F.; de Hoog, S.; Santos, D.W.C.L.; Salgado, C.G.; Vicente, V.A.; Bonifaz, A.; Rolides, E.; Xi, L.; de Maria Pedrozo, E.; Silva Azevedo, C.; et al. Chromoblastomycosis. *Clin. Microbiol. Rev.* 2017, 30, 233–276. [CrossRef] [PubMed]
11. Arenas, R.; Vega-Mémine, M.E.; Rangel-Gamboa, L. Eumycetoma: Actualidades y perspectivas. *Gac. Med. Mex.* 2017, 153, 841–851.
12. Van de Sande, W.; Fahal, A.; Ahmed, S.A.; Serrano, J.A.; Bonifaz, A.; Zijlstra, E.; Eumycetoma Working Group. Closing the mycetoma knowledge gap. *Med. Mycol.* 2018, 56 (Suppl. S1), 153–164. [CrossRef] [PubMed]
13. Borman, A.M.; Desnos-Ollivier, M.; Campbell, C.K.; Bridge, P.D.; Dannaoui, E.; Johnson, E.M. Novel taxa associated with human fungal black-grain mycetomas: *Enarellia grisea* gen. nov., sp. nov., and *Enarellia paragrisea* sp. nov. *J. Clin. Microbiol.* 2016, 54, 1738–1745. [CrossRef] [PubMed]
41. Lawrence, D.P.; Rotondo, F.; Gannibal, P.B. Biodiversity and taxonomy of the pleomorphic genus Alternaria. Mycol. Prog. 2016, 15, 3. [CrossRef]
42. Gannibal, P.B.; Lawrence, D.P. Distribution of Alternaria species among sections. 3. Sections Infectoriae and Pseudoalternaria. Mycotaxon 2016, 131, 718–790.
43. Brunet, K.; Alanio, A.; Lortholary, O.; Rammaert, B. Reactivation of dormant/latent fungal infection. J. Infect. 2018, 77, 463–468. [CrossRef] [PubMed]
44. Agrawal, N.; Jones, D.E.; Dyson, J.K.; Hoare, T.; Melmore, S.A.; Needham, S.; Thompson, N.P. Fatal gastrointestinal histoplasmosis 15 years after orthotopic liver transplantation. World J. Gastroenterol. 2017, 23, 7807–7812. [CrossRef] [PubMed]
45. Majeed, A.; Kapoor, V.; Latif, A.; Zangeneh, T. A 30-year delayed presentation of disseminated histoplasmosis in a heart transplant recipient: Diagnostic challenges in a non-endemic area. BMJ Case Rep. 2017, 2017, bcr2017222012. [CrossRef] [PubMed]
46. Garcia-Hermoso, D.; Janbon, G.; Dromer, F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 1999, 37, 3204–3209. [CrossRef] [PubMed]
47. Ahmed, J.; Ditmars, D.M.; Sheppard, T.; del Busto, R.; Venkat, K.K.; Parasuraman, R. Recurrence of Scedosporium apiospermum infection following renal re-transplantation. Am. J. Transplant. 2004, 4, 1720–1724.
48. Polak, A. Melanin as a virulence factor in pathogenic fungi. Mycoses 1990, 33, 215–224. [CrossRef] [PubMed]
49. Jacobson, E.S. Pathogenic roles for fungal melanins. Clin. Microbiol. Rev. 2000, 13, 708–717. [CrossRef]
50. Taborda, C.P.; da Silva, M.B.; Nosanchuk, J.D.; Travassos, L.R. Melanin as a virulence factor of Paracoccidioides brasiliensis and other dimorphic pathogenic fungi: A minireview. Mycopathologia 2008, 165, 331–339. [CrossRef] [PubMed]